Buradasınız

Anasayfa » Content

Son Dönem Böbrek Yetmezlikli Hastalarda Malnütrisyon-înflamasyon-Ateroskleroz (MİA Sendromu)

Malnutrition-Inflammation-Atherosclerosis (MIA Syndrome) in ESRD Patients

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Malnutrition, inflammation and accelerated atherosclerosis are common in end-stage renal disease (ESRD) patients. All these parameters are the causes of morbidity and mortality in this population. It is known that ESRD patients had a high level of pro-inflammatory cytokine and serum C-reactive protein. MIA syndrome was defined as the interaction between increased pro-inflammatory cytokine and malnutrition and atherosclerosis in ESRD patients by Stenvinkel et al in 2000. As the components of MIA syndrome increase, the morbidity and mortality increase and survival decreases in ESRD patients. For this reason it is supposed that morbidity and mortality would decrease and survival would increase with the treatment of malnutrition, inflammation and atherosclerosis.
Bookmark/Search this post with
Abstract (Original Language): 
Kronik böbrek yetmezlikli hastalarda malnütrisyon, inflamasyon ve akselere ateroskleroz gelişimine sık rastlanmaktadır. Her üç parametre de son dönem böbrek yetmezlikli (SDBY) hastalarda ayrı ayrı morbidite ve mortalite nedenidir. SDBY hastalarının yüksek proinflamatuar sitokin düzeylerine ve yüksek CRP (C-reaktif protein) düzeyine sahip olduğu bilinmektedir. 2000 yılında Stenvinkel ve arkadaşları tarafından ortaya atılan MİA sendromunun veya hipotezinin temelini; SDBY hastalarında artmış serum proinflamatuar sitokin düzeyleri ile bu hastalarda sıklıkla görülen malnütrisyon ve başlıca morbidite ve mortalite nedeni olan akselere ateroskleroz gelişimi arasındaki ilişki oluşturmaktadır. MİA sendromunun komponentlerinin artmasıyla SDBY hastalarında morbidite ve mortalite artmakta ve yaşam süresi azalmaktadır. Bu nedenle SDBY hastalarında malnütrisyon, inflamasyon ve akselere ateroskleroz gelişimi ile etkin mücadele edilmesinin morbiditeyi ve mortaliteyi azaltacağı ve yaşam süresini uzatacağı düşünülmektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_542.pdf
  • 4
160-165
  • Turkish

REFERENCES

References: 

1. Bergström J, Lindholm B. Malnutrition, cardiac disease and mortality: an integrated view of point. Am J Kidney Dis 1998; 32: 834-841.
2. Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergström J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutriti¬on, inflammation and atherosclerosis (MIA syndrome). Neph-rol Dial Transplant 2000; 15: 953-960.
3. Stenvinkel P, Chung SH, Heimbürger O, Lindholm B. Malnut¬rition, inflammation and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001; 21: 157-160.
4. Weekes CE, Elia M, Emery PW. The development, validation and reliability of a nutrition screening tool based on the re¬commendations of the British Association for Parenteral and
Enteral Nutrition (BAPEN). Clin Nutr 2004; 23: 1104-1112.
5. Slomowitz LA, Monteon FJ, Grosvenor M, Laidlaw S, Kopple JD. Effect of energy intake on nutritional status in maintenan¬ce hemodialysis patients. Kidney Int 1989; 35: 704-711.
6. Don BR, Kaysen GA. Assessment of inflammation and nutri¬tion in patients with end-stage renal disease. J Nephrol 2000;
13: 249-259.
7. Wang AY, Woo J, Wang M, et al. Association of inflammati¬on and malnutrition with cardiac valve calcification in conti¬nuous ambulatory peritoneal dialysis patients. J Am Soc
Nephrol 2001; 12: 1927-1936.
8. Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvin-kel P. Hand-grip muscle strength, lean body mass, and plas¬ma proteins as marker of nutritional status in patients with chronic renal failure close to start to dialysis therapy. Am J Kidney Dis 2000: 6; 1213-1225.
9. Kalantar-Zadeh K, Kleiner M, Dunne E, Lee GH, Luft FC. A modified quantitative subjective global assessment of nutrition for dialysis patients. Nephrol Dial Transplant 1999; 14: 1732-1738.
10. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-Inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 2003; 42: 864-881.
11. Monteon FJ, Laidlaw SA, Shaib JK, Kopple JD. Energy expenditure in patients with chronic renal failure. Kidney Int 1986;
30: 741-747.
12. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim
RM. Increased energy expenditure in hemodialysis patients. J
Am Soc Nephrol 1996; 7: 2646-2653.
13. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J
Am Soc Nephrol 1998; 9: 2368-2376.
14. Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int
1995; 48: 510-516.
15. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dina-rello CA. Plasma levels of IL-1 beta, TNF alpha and their spe¬cific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890-896.
16. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in hemodialysis patients. Kidney Int
1998; 54: 236-244.
17. Bistrian BR, Schwartz J, Istfan NW. Cytokines, muscle prote-olysis, and the catabolic response to infection and inflamma¬tion. Proc Soc Exp Biol Med 1992; 200: 220-223.
18. Plata-Salaman CR. Cytokines and anorexia: a brief overview.
Semin Oncol 1998; 25: 64-72.
164
Türk
Nefroloj
i Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Son Dönem Böbrek Yetmezlikli Hastalarda Malnütrisyon-İnflamasyon-Ateroskleroz (MİA Sendromu) £
19. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alp-ha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998;
13: 1476-1483.
20. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong associati¬on between malnutrion, inflammation and atherosclerosis in
chronic renal failure. Kidney Int 1999; 55: 1899-1911.
21. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 1: 36-40.
22. Memoli B, Postiglione L, Cianciaruso B, et al. Role of diffe¬rent dialysis membranes in the release of interleukin-6-solub-le receptor in uremic patients. Kidney Int 2000; 58: 417-424.
23. Means RT Jr, Krantz SB. Progress in understanding the pat-hogenesis of the anemia of chronic disease. Blood 1992; 80:
1639-1647.
24. Macdougall IC. Role of uremic toxins in exacerbating anemia
in renal failure. Kidney Int 2001; 78: 67-72.
25. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 pre¬dicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
26. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibi¬ting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50: 301¬308.
27. Mitch WE, Du J, Bailey JL, Price SR. Mechanisms causing muscle proteolysis in uremia: the influence of insulin and
cytokines. Miner Electrolyte Metab 1999; 25: 216-219.
28. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovasculer risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
29. Walter R, Mischak H, and Haller H. Haemodialysis, atherosc¬lerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. Nephrol Dial
Transplant 2002;17: 24-29.
30. Ohkuma T, Minagawa T, Takada N, Ohno M, Oda H, Ohas-
hi H. C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis. 2003; 42: 355-361.
31. Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai H, His-hida A. Association between interleukin-6 and carotid athe¬rosclerosis in hemodialysis patients. Kidney Int 2002; 61:
1143-1152.
32. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interle-ukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae se-
ropositivity. Am J Kidney Dis 2002; 2: 274-282.
33. Papagianni A, Kokolina E, Kalovoulos M, Vainas A, Dimitri-adis C, Memmos D. Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion mole-cule-1 in patients on continuous ambulatory peritoneal dialy¬sis. Nephrol Dial Transplant 2004; 19: 1258-1263.
34. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethy-larginine, C-reactive protein, and carotid intima-media thick¬ness in end-stage renal disease. J Am Soc Nephrol 2002; 13:
490-496.
35. Bolton CH, Downs LG, Victory JG, et al. Endothelial dysfunc¬tion in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant
2001; 16: 1189-1197.
36. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-340.
37. Mezzano D, Pais EO, Aranda E. Inflammation, not hyperho-mocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60: 1844-1850.
38. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in he-modialysis patients: Role of inflammation. Am J Kidney Dis
2002; 40: 340-353.
39. Yeun JY and Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol
Hypertens 2000; 9: 621-630.
40. Prichard S. Major and minor risk factors for cardiovascular di¬sease in continuous ambulatory peritoneal dialysis patients.
Perit Dial Int 1999; 19: 133-137.

Thank you for copying data from http://www.arastirmax.com